Literature DB >> 2556076

Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites.

K Akahane1, M Sekiguchi, T Une, Y Osada.   

Abstract

The relationship between the chemical structure and epileptogenic activity of quinolones was investigated. When the quinolones were administered intravenously to mice concomitantly with oral biphenylacetic acid, a major metabolite of the nonsteroidal antiinflammatory drug fenbufen, enoxacin, norfloxacin, ciprofloxacin, and pipemidic acid, which have an unsubstituted piperazine moiety at the 7 position of their parent nuclei, provoked clonic convulsions and subsequent death at doses of 6.25 mg/kg or more in a dose-dependent manner. AM-1091 and T-3262, which have an unsubstituted aminopyrrolidine moiety at their 7 positions, were less epileptogenic than the compounds listed above were. In contrast, ofloxacin, AT-4140, and nalidixic acid, which have piperazine substituted with methyl group(s) or no piperazine moiety at their 7 positions, never induced convulsions, even at doses of 100 mg/kg. Lomefloxacin, which has a 3-methyl piperazine, however, provoked convulsions at doses of 6.25 mg/kg or more. In the presence of biphenylacetic acid, all the test quinolones except nalidixic acid competitively inhibited [3H]muscimol binding to receptor sites for gamma-aminobutyric acid (GABA) in vitro. Nalidixic acid did not inhibit the binding at all, even at the highest concentration tested, i.e., 10(-4) M. The 50% inhibition doses for [3H]muscimol binding varied within 4 orders of magnitude or more, between 10(-8) to more than 10(-4) M for various compounds, and there was a close correlation between the epileptogenic activities of quinolones and their inhibitory potencies for [3H]muscimol binding to GABA receptor sites. These results indicate that the epileptogenic activity of quinolones possibly relates to the GABA-like structures of substituents at their 7 positions, which act as antagonists of GABA receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556076      PMCID: PMC172741          DOI: 10.1128/AAC.33.10.1704

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Neurological toxicity related to pefloxacin.

Authors:  J C Lucet; H Tilly; G Lerebours; J J Gres; H Piguet
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

2.  Norfloxacin and seizures.

Authors:  G D Anastasio; D Menscer; J M Little
Journal:  Ann Intern Med       Date:  1988-07-15       Impact factor: 25.391

3.  Convulsions related to enoxacin.

Authors:  K J Simpson; M J Brodie
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

Review 4.  Overview of drug interactions with the quinolones.

Authors:  P G Davey
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

5.  Ciprofloxacin: an update on clinical experience.

Authors:  G Arcieri; E Griffith; G Gruenwaldt; A Heyd; B O'Brien; N Becker; R August
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

Review 6.  Ciprofloxacin: an overview of adverse experiences.

Authors:  P Ball
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

Review 7.  Adverse effects of the fluoroquinolones.

Authors:  H Halkin
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

8.  In vitro and in vivo antibacterial activity of AT-2266.

Authors:  K Kouno; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

Review 9.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

10.  Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes.

Authors:  A Tsuji; H Sato; Y Kume; I Tamai; E Okezaki; O Nagata; H Kato
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

View more
  36 in total

1.  Correlation between quinolone uptakes by BCECs in vitro and brain-to-plasma concentration ratios in rats.

Authors:  X D Liu; D W Wang; L Xie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

Review 2.  Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

Authors:  H Lode
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 3.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  Seizures and quinolone antibiotics in children: a systematic review of adverse events.

Authors:  Matthew Neame; Charlotte King; Andrew Riordan; Anand Iyer; Rachel Kneen; Ian Sinha; Daniel B Hawcutt
Journal:  Eur J Hosp Pharm       Date:  2019-01-28

Review 5.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Interaction between enoxacin, a new antimicrobial, and nimesulide, a new non-steroidal anti-inflammatory agent in mice.

Authors:  Y Taniguchi; Y Deguchi; K Noda
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

7.  Effects of novel 6-desfluoroquinolones and classic quinolones on pentylenetetrazole-induced seizures in mice.

Authors:  A De Sarro; V Cecchetti; V Fravolini; F Naccari; O Tabarrini; G De Sarro
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  Accidental overdose of intravenous ofloxacin with benign outcome.

Authors:  R B Kohler; N Arkins; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

Review 9.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

10.  Quinolones potentiate cefazolin-induced seizures in DBA/2 mice.

Authors:  A De Sarro; M Zappalá; A Chimirri; S Grasso; G B De Sarro
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.